Anavex Life Sciences (AVXL) EPS (Basic) (2016 - 2025)
Anavex Life Sciences (AVXL) posted EPS (Basic) of -$28.7 for Q4 2025, up 93.84% sequentially from -$465.78 in Q3 2025, and down 2843.41% YoY from $1.05 in Q4 2024.
Anavex Life Sciences (AVXL) EPS (Basic) (2016 - 2025) Analysis & Trends
Anavex Life Sciences has reported EPS (Basic) for 10 years, with the latest figure at -$28.7 in Q4 2025.
- Quarterly EPS (Basic) fell 2843.41% year-over-year to -$28.7 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$476.17 (down 34354.77% YoY) and the FY2025 annual result came in at -$466.26, down 90402.24% from the prior year.
- EPS (Basic) climbed to -$28.7 in Q4 2025 per AVXL's latest filing, from -$465.78 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.11 in Q4 2023 and troughed at -$465.78 in Q3 2025.
- A 5-year average of -$24.95 and a median of -$0.15 in 2022 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2023 and 2025: EPS (Basic) jumped 36.85% in 2023, then sank 330946.27% in 2025.
- Over 5 years, EPS (Basic) stood at -$0.14 in 2021, then declined by 16.18% to -$0.17 in 2022, then jumped by 36.85% to -$0.11 in 2023, then plunged by 828.31% to -$0.98 in 2024, then slumped by 2843.41% to -$28.7 in 2025.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$28.7, -$465.78, and -$0.71 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 7.59 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.06 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.16 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.18 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.23 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.06 |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | -28.70 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -28.70 |
| Sep 30, 2025 | -465.78 |
| Jun 30, 2025 | -0.71 |
| Mar 31, 2025 | -0.60 |
| Dec 31, 2024 | -0.98 |
| Sep 30, 2024 | -0.14 |
| Jun 30, 2024 | -0.14 |
| Mar 31, 2024 | -0.13 |
| Dec 31, 2023 | -0.11 |
| Sep 30, 2023 | -0.13 |
| Jun 30, 2023 | -0.14 |
| Mar 31, 2023 | -0.17 |
| Dec 31, 2022 | -0.17 |
| Sep 30, 2022 | -0.19 |
| Jun 30, 2022 | -0.16 |
| Mar 31, 2022 | -0.14 |
| Dec 31, 2021 | -0.14 |
| Sep 30, 2021 | -0.17 |
| Jun 30, 2021 | -0.14 |
| Mar 31, 2021 | -0.12 |